Subscribe to the SLI Medical mailing list to receive updates on new arrivals, special offers and our promotions.
The store will not work correctly in the case when cookies are disabled.
Get Up to 25% OFF PPE MasksGowns * Limited time only.
SLI MEDICAL IS A WHOLESALE SITE! WE ONLY SELL TO QUALIFIED FACILITIES (Such As Hospitals, Physician Offices, & Distributors). All Addresses are Verified.
For use with BD Veritor System / SARS-CoV-2 and Flu A+B
Form
Swab
HCPCS
U0002
Levels
Positive Level
Product Dating
SLI Medical Acceptable Dating: we will ship >= 30 days
Test Name
SARS-CoV-2 / Flu A+B
Test Type
Antigen Detection
UNSPSC Code
41116144
Features
BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B Positive Control Swab set – 10 of each analyte
BD Veritor System for Rapid Detection of SARS-CoV-2 and Flu A+B is For use under an Emergency Use Authorization only: https:www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
This product is only for use under Emergency Use Authorization in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
42 U.S.C. §263a
that meet the requirements to perform moderate
high
or waived complexity tests and operating under a CLIA Certificate of Waiver
Certificate of Compliance
or Certificate of Accreditation
Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
42 U.S.C. §263a
that meet the requirements to perform moderate
high
or waived complexity tests
Positive results indicate the presence of viral antigens
but clinical correlation with patient history and other diagnostic information is necessary to determine infection status
Positive results do not rule out bacterial infection or co-infection with other viruses
Laboratories within the United States and its territories are required to report all SARS-CoV-2 results to the appropriate public health authorities
Negative results should be treated as presumptive
do not rule out either Influenza or SARS-CoV-2
and should not be used as the sole basis for treatment or patient management decisions
including infection control decisions
Negative results shoul d be considered in the context of a patient’s recent exposures
history and the presence of clinical signs and symptoms consistent with one of these infections
Negative results for SARS-CoV-2 should be confirmed with a molecular assay
if necessary
for patient management
The BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B is intended for use in point of care settings by trained healthcare professionals or other users specifically instructed in the use of BD Veritor Systems and proper infection control procedures
